SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention after a recent rebound that traders say held its gains, with bullish technical setups and positioning ahead of earnings. The upbeat view contrasts with concerns that high rates and a sluggish housing market could continue to weigh on renovation demand.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sharp rally to fresh multi-year highs is drawing attention, with traders citing rotation into defensive, dividend-paying pharma stocks and positioning ahead of the quarterly report. Bulls see a technical breakout and pipeline momentum, while skeptics warn the move may meet resistance and point to patent-expiration and growth concerns.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,397.34014094 USD and is up 0.28 over the last 24 hours. It is currently trading on 12773 active market(s) with $12,152,377,915.37 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention amid concerns over Binances reported major hack and paused withdrawals, with traders debating whether damaged exchange trust could trigger further selling. Others argue the market is absorbing the shock and point to Binances reported reimbursement progress and planned withdrawal reopening as reasons for optimism.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on expected Q3 results and the Phase 3 QUILT-2.005 topline for ANKTIVA plus BCG in BCG-naive bladder cancer; the trial is database-locked, with a supplemental filing planned if results support it. Bullish traders see the readout and ANKTIVAs expanded bladder-cancer label as growth catalysts, while others question commercial uptake and point to competition, short-selling, and broader market weakness to explain the volatility.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders use the leveraged inverse Nasdaq ETF to hedge or bet on further weakness in tech, citing concerns about AI spending and valuations alongside recent tech-led selling. The community is divided: some expect more downside, while others warn that rumors of a U.S.Iran deal and a possible market rebound could reverse gains in the short ETF.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow is being discussed amid volatile, uneven trading across major indexes, with traders watching Fed policy and rising Treasury yields as pressures on equities. Some see relative strength in the Dow as money rotates away from tech, while others warn that inflation, oil-market risks and weakening momentum could deepen a selloff.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Discussion centers on BioCrysts upcoming quarterly results and whether continued ORLADEYO growth can support the stock despite its weak performance. Traders are also looking ahead to Navenibart and Netherton data, while debating managements acquisition strategy and expressing frustration over dilution and limited shareholder returns; buyout talk remains speculative.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results and outlook are drawing attention, with traders highlighting stronger streaming profitability and resilient theme-park performance. The reaction is mixed: some see support for a turnaround, while others point to the stocks persistent range-bound price action and difficulty holding gains.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention ahead of its upcoming earnings report, with traders watching whether guidance holds and how management addresses pressure on the pharmacy benefit management business. Some see the recent pullback as a potential technical rebound setup, while others remain cautious after the stocks recent selling.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

A sharp volatility spike has lifted UVIX, drawing traders seeking a hedge against a broader market pullback. The community is split between expecting volatility to persistciting concerns about oil, interest rates and geopolitical risksand warning that UVIX can quickly lose value as volatility fades and its leveraged futures exposure decays.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traders are positioning around upcoming earnings after AXONs prolonged pullback, with bulls viewing the weakness as a buying opportunity and bears pointing to its high valuation and dilution and margin concerns. The discussion also reflects uncertainty over whether the recent bounce can hold.

Axon Enterprise vs. ServiceNow: Which Industrials Stock Is a Better Buy in 2026?

Key PointsAxon Enterprise maintains a dominant position in public safety technology with high revenue growth and a growing cloud software user base...

Axon Enterprise vs. Fastly: Which Industrials Stock Is a Better Buy in 2026?

Key PointsAxon Enterprise maintains a dominant position in public safety technology with an integrated ecosystem of hardware and high-margin cloud software...

Axon Enterprise vs. DocuSign: Which Industrials Stock Is a Better Buy in 2026?

Key PointsAxon Enterprise maintains a powerful ecosystem by integrating public safety hardware with cloud-based software services...

Axon Enterprise (AXON) Registers a Bigger Fall Than the Market: Important Facts to Note

Axon Enterprise (AXON) closed at $427.77 in the latest trading session, marking a -2.35% move from the prior day.

Axon Enterprise (AXON) Reports Next Week: Wall Street Expects Earnings Growth

Axon (AXON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It

Axon (AXON) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

$1000 Invested In Axon Enterprise 5 Years Ago Would Be Worth This Much Today

Axon Enterprise (NASDAQ:AXON) has outperformed the market over the past 5 years by 7.87% on an annualized basis producing an average annual return of 18.71%. Currently, Axon Enterprise has a market capitalization ofread more...

Axon Announces Body 5: Next-Generation Camera Built for the AI Era

Axon Announces Body 5: Next-Generation Camera Built for the AI Era Axon Announces Body 5: Next-Generation Camera Built for the AI EraPR NewswireSCOTTSDALE, Ariz., Oct. 24, 2026 Axon Body 5 delivers 25x the AI processing power of earlier-generation cameras, with upgraded connectivity, audio and...

Axon to Release Third Quarter 2026 Earnings on November 5, 2026

Axon to Release Third Quarter 2026 Earnings on November 5, 2026 Axon to Release Third Quarter 2026 Earnings on November 5, 2026PR NewswireSCOTTSDALE, Ariz., Oct. 22, 2026 SCOTTSDALE, Ariz., Oct. 22, 2026 /PRNewswire/ -- Axon(Nasdaq: AXON), the global public safety technology leader, today announced...

Why Axon Enterprise (AXON) Outpaced the Stock Market Today

Axon Enterprise (AXON) reached $403.02 at the closing of the latest trading day, reflecting a +2.64% change compared to its last close.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

AXON Plans To Raise $1B Through Convertible Notes — Here’s What Investors Need To Know

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Axon expects to give underwriters an option to purchase up to an additional $150 million of notes to cover over-allotments.</li><li>The notes will mature on Sept. 15, 2031, will carry no regular interest and will not accrete in principal.</li><li>Axon expects to enter into capped call transactions designed to generally reduce potential dilution upon conversion of the notes, subject to a cap.</li></ul><p>Axon Enterprise Inc. (AXON) shares fell around 4% in Tuesday’s premarket session after the public safety technology company announced plans to raise $1 billion through an offering of 0% convertible senior notes due 2031.</p><p>Axon also expects to grant the underwriters an option to purchase up to an additional $150 million of notes solely to cover any over-allotments.</p><h2 class="st-heading-2">Use Of Proceeds</h2><p>Axon said it intends to use a portion of the net proceeds to pay the costs of the capped call transactions tied to the notes.</p><p>The company expects to use the remaining net proceeds for general corporate purposes, including providing capital to support its growth and acquiring or investing in product lines, products, services or technologies.</p><h2 class="st-heading-2">Axon’s 0% Convertible Notes</h2><p>The notes will mature on Sept. 15, 2031, unless converted, redeemed or repurchased earlier. The notes will be senior, unsecured obligations of Axon and will not bear regular interest. The principal amount will also not accrete, the firm said.</p><p>Noteholders will have the right to convert their notes under certain circumstances and during specified periods. Upon conversion, Axon may settle the obligation in cash, common stock, or a combination of both.</p><p>The initial conversion rate and other terms of the notes will be determined when the offering is priced. This means the number of shares that could be involved in a future conversion cannot be determined from Tuesday's announcement alone.</p><p>Alongside the offering, Axon said it expects to enter into privately negotiated capped call transactions with one or more financial institutions.</p><p>The capped calls will cover the number of shares initially underlying the notes, subject to anti-dilution adjustments.</p><p>Axon said the transactions are generally designed to reduce potential dilution of its common stock upon conversion of the notes and/or to offset certain cash payments it may be required to make above the principal amount of the converted notes, subject to a cap.</p><h2 class="st-heading-2">Axon’s Existing Debt And Cash Position</h2><p>As of June 30, 2026, Axon reported $685 million in cash, cash equivalents and short-term investments and $1.8 billion of outstanding senior notes, leaving the company with a net debt position of approximately $1.1 billion.</p><p>The new notes would therefore add to Axon's debt obligations if the proposed offering is completed, although the 0% coupon means the notes would not require regular cash interest payments.</p><h2 class="st-heading-2">Axon's Earnings Highlights</h2><p>The company reported $904 million in second-quarter (Q2) revenue, up 35% year over year, marking its 10th consecutive quarter of revenue growth above 30%. Annual recurring revenue rose 39% to $1.6 billion.</p><p>Axon reported $15.1 billion in future contracted bookings as of June 30, up 41% year over year. The company said it expected to fulfill 20% to 25% of that balance over the next 12 months, with the remainder generally expected to be fulfilled over the following 10 years.</p><p>The firm raised its full-year 2026 revenue-growth outlook to 32% to 34% from 30% to 32% previously, while maintaining its Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA)&nbsp; margin outlook at approximately 25.5%.</p><h2 class="st-heading-2">Retail Take On AXON</h2><p>On Stocktwits, retail sentiment for AXON stayed ‘neutral’ over the past 24 hours.</p><p><a href="https://stocktwits.com/symbol/AXON">AXON</a> stock has dropped over 15% year-to-date.</p><p><strong>Read more: </strong><a href="https://stocktwits.com/news-articles/markets/equity/vera-stock-jumps-16-premarket-trutakna-cuts-kidney-disease-progression-risk-by-76-full-fda-filing-planned-in-q4/cZtnakYRBcI"><strong>VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 Axon Enterprise Logo Shown on Smartphone with Latest Stock Market Chart

Axon plans to offer $1 billion of 0% convertible senior notes due 2031, with proceeds earmarked for capped call costs and general corporate purposes, including growth initiatives and potential acquisitions or investments in other businesses.

$APP

$AXON

$BROS

$CELH

$APP, $AXON, $BROS, and $CELH all sold off sharply following Q2 earnings. Which of these earnings declines are you most interested in buying? Vote and explain your reasoning in the comments.

Which of these earnings declines are you most interested in buying - $APP, $AXON, $BROS, or $CELH?

Current Price	$427.77
Prev Close	$438.05
Open	$430.52
Dividend Yield	0.00%
50-Day Moving Average	$463.44
Beta	1.21
Avg. Volume	1.09M
PE Ratio	177.16

52-Week High	$738.23
52-Week Low	$339.01
Market Capitalization	$34.75B
EPS (Annual)	$1.51
Price to Book	9.46
Revenue Per Employee	$441,196.19

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXON Fundamentals